Email alerts

Subscribe to our mailing list

Testimonials

Since Tri-Solfen® was commercially launched, over 80 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Close

Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
New
Zealand
Sheep,
Cattle
Granted
New
Zealand
Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
Cattle
Granted
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Cattle
Granted
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Pig
Granted
Canada Humans Granted

Close

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Close

Mulesing Pain Relief Uptake Increases to 58%

December 22, 2015

Sheep producers increase use of pain relief for mulesing at a cost of $4.5 million in 2014

ABC Rural, By Sarina Locke

The use of pain relief after surgical mulesing of sheep increased by 10 per cent in 2014, compared to the previous year.

The anaesthetic spray Tri-Solfen has only been available since 2011 and this is the first time the developer, Animal Ethics Pty Ltd, has released sensitive sales data.

It shows 58 per cent of all lambs that had the skin cut away from the breech, for a lifetime protection against fly strike, were given a spray of Tri-Solfen.

The flip-side is 42 per cent of lambs received no pain relief.

AUDIO: Pain relief uptake for mulesing operation increases by 10 per cent (ABC Rural)

Animal Ethics managing director Allan Giffard said pain relief use was highest in South Australia, and lowest in Queensland.

  • 82 per cent of South Australian lambs received pain relief
  • 72 per cent of Victorian and Tasmanian lambs received pain relief
  • 65 per cent of lambs in NSW received pain relief
  • 55 per cent in Western Australia received pain relief
  • 16 per cent in Queensland, of a total of 900,000 lambs, received pain relief

Italian and British wool textile makers have repeated calls for pain relief to be compulsory after mulesing, which the wool industry has rejected.

Animal Ethics Pty Ltd said at a cost of 50 to 60 cents per dose, sheep producers nationally spent more than $4.5 million on pain relief last year.

Mr Giffard said it was positive to see the increased take-up of pain relief.

Of the 14.3 million lambs mulesed in 2014, just over nine million were treated with pain relief.

The company used figures based on Australian Wool Innovation breech surgery statistics, as well as Tri-Solfen sales, to arrive at the final number.

“In Queensland there are a bit over 900,000 lambs mulesed, and of that we had treatment rates of 148,000 lambs with pain relief in mulesing, ” Mr Giffard said.

“Tri-Solfen works in four different ways; stopping the pain when applied to the nerve endings, it stops the bleeding, it stops the infection and it’s been shown by Sydney University to improve the wound healing rates quite dramatically as well,” he said.

The company said it was researching a practical way to give lambs pain relief prior to mulesing.   FULL ARTICLE